Key result
Prior NSVT linked to ~4.7-fold higher heart failure mortality in primary-prevention CRT-D patients.
Why the study?
Does a prior history of nonsustained ventricular tachycardia (NSVT) predict heart failure death or sudden cardiac death in patients receiving CRT-D for primary prevention?
Cohort (n=269)
Yes
Does a prior history of nonsustained ventricular tachycardia (NSVT) predict heart failure death or sudden cardiac death in patients receiving CRT-D for primary prevention?
Answers are grounded in this paper and cite their sources.
A prior history of NSVT in CRT-D recipients acts as a marker of severe heart failure and higher heart failure mortality risk, rather than as a specific substrate for sustained ventricular arrhythmias requiring ICD therapy.
Background Whether nonsustained ventricular tachycardia ( NSVT ) is a marker of increased risk of sustained ventricular tachyarrhythmias ( VTA s) remains to be established in patients receiving cardiac resynchronization therapy with a defibrillator ( CRT ‐D) for primary prevention. Methods Among the follow‐up data of the Japan cardiac device treatment registry ( JCDTR ) with an implantation date between January 2011 and August 2015, information regarding a history of NSVT before the CRT ‐D implantation for primary prevention had been registered in 269 patients. Outcomes were compared between two groups with and without NSVT : NSVT group (n = 179) and No NSVT group (n = 90). Results There was no significant difference with regard to age, gender, and NYHA class between the two groups. Left ventricular ejection fraction ( LVEF ) was 25.6% in the NSVT group and 28.0% in the No NSVT group ( P = .046). The rate of appropriate therapy at 24 months was 26.0% and 18.4% in the NSVT and No NSVT groups ( P = .22), respectively. Survival free from heart failure death was reduced in the NSVT group, as compared with the No NSVT group, with the rate of 90.2% vs 97.2% at 24 months ( P = .030). A multivariate analysis identified a history of NSVT , anemia, and no use of angiotensin‐converting enzyme inhibitor ( ACEI ) or angiotensin‐receptor blocker ( ARB ) as predictors of heart failure death. Conclusions NSVT appears to be a surrogate marker of severe heart failure rather than a substrate for subsequent sustained VTA s in patients with CRT ‐D for primary prevention.
No takes yet. Share an insight, caveat, or question.
Yokoshiki et al. (2018) conducted a cohort in Heart failure requiring CRT-D for primary prevention (n=269). Nonsustained ventricular tachycardia (NSVT) vs. No prior history of NSVT was evaluated on Heart failure death (HR 4.73, 95% CI 1.09-20.43, p=0.037). A prior history of nonsustained ventricular tachycardia was associated with a increased risk of heart failure death in patients receiving CRT-D for primary prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: